KD-182 / KAEDI - LARVOL DELTA

Tandem CAR-T cells targeting CLDN18.2 and NKG2DL for treatment of gastric cancer. (ASCO 2022) - "Our work construct a tandem CAR molecule targeting two tumor-associated antigens, NKG2DL and CLDN18.2, and found that Tan-CAR-T cells（KD-496）distinctly recognize the antigens and exhibited superior antitumor effect. KD-496 CAR-T cells potently respond to GC and more efficient tumor elimination than single CAR such as KD-025 and KD-182 CAR-T cells in PDX model with no obvious safety issue. The results support future clinical trial of KD-496 CAR in patients with GC, where the need for effective treatment is great."

CAR T-Cell Therapy • IO biomarker • Gastric Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor • CD8 • CLDN18 • CLDN8 • IFNG • NKG2D